Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
Autor: | Hee Kyung Ahn, Eun Joo Kang, Seong Hoon Shin, Sung-Bae Kim, Y. Lee, Keon Uk Park, Jung Hye Kwon, Kyoung Eun Lee, Keun Wook Lee, Hwan Jung Yun, Hye Ryun Kim, Min Kyoung Kim, Jin-Soo Kim, Jin-Hyuk Choi, Bhumsuk Keam |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_treatment Cetuximab Docetaxel 0302 clinical medicine Antineoplastic Agents Immunological Squamous cell carcinoma Antineoplastic Combined Chemotherapy Protocols Locally advanced head and neck cancer Aged 80 and over Chemoradiotherapy Induction Chemotherapy Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Progression-Free Survival Survival Rate Head and Neck Neoplasms 030220 oncology & carcinogenesis Female Fluorouracil medicine.drug Research Article Adult medicine.medical_specialty Antimetabolites Antineoplastic Strategy lcsh:RC254-282 03 medical and health sciences Young Adult Internal medicine Genetics medicine Humans Aged Retrospective Studies business.industry Squamous Cell Carcinoma of Head and Neck Induction chemotherapy Retrospective cohort study Multidisciplinary treatment medicine.disease Head and neck squamous-cell carcinoma Radiation therapy Regimen 030104 developmental biology Nasopharyngeal carcinoma Cisplatin business Follow-Up Studies |
Zdroj: | BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Methods This is a multi-institutional study enrolled the patients with stage III to IVB LA-HNSCC, except for nasopharyngeal carcinoma, from 2004 to 2015 in thirteen referral hospitals capable of multidisciplinary care. Results A total of 445 LA-HNSCC patients were analyzed. The median age was 61 years (range, 24–89). The primary tumor location was the oropharynx in 191 (43%), oral cavity in 106 (24%), hypopharynx in 64 (14%), larynx in 57 (13%) and other sites in 27 (6%). The most common stage was T2 in 172 (39%), and N2 in 245 (55%). Based on treatment intents, 229 (52%) of the patients received definitive concurrent chemoradiotherapy (CCRT) and 187 (42%) underwent surgery. Approximately 158 (36%) of the study population received induction chemotherapy (IC). Taken together, 385 (87%) of the patients underwent combined therapeutic modalities. The regimen for definitive CCRT was weekly cisplatin in 58%, 3-weekly cisplatin in 28% and cetuximab in 3%. The preferred regimen for IC was docetaxel with cisplatin in 49%, and docetaxel, cisplatin plus fluorouracil in 27%. With a median follow-up of 39 months, one-year and two-year survival rates were 89 and 80%, respectively. Overall survival was not significantly different between CCRT and surgery group (p = 0.620). Conclusions In patients with LA-HNSCC, the majority of patients received combined therapeutic modalities. Definitive CCRT, IC then definitive CCRT, and surgery followed by adjuvant CCRT or radiotherapy are the preferred multidisciplinary strategies in real-world practice. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |